||Impact of Synchronous Multiple Primary Malignant Tumors on Newly Diagnosed Hematological Malignancies
Nishiwaki, Satoshi ,
Okuno, Shingo ,
Suzuki, Kotaro ,
Kurahashi, ShingoSugiura, Isamu
Clinical Lymphoma Myeloma and Leukemia
e85 , 2017-12 , Elsevier
The existence of synchronous multiple primary malignant tumors was not a significant risk factor for patientswith newly diagnosed hematological malignancies. It is important to provide adequate treatment to bothhematological malignancies and solid tumors appropriately.Background: Hematological malignancies are occasionally observed with synchronous multiple primary malignanttumors (sMPMTs) at diagnosis. We aimed to clarify the impact of sMPMTs on newly diagnosed hematological malignanciesand determine the optimal treatment strategies. Patients and Methods: We analyzed the outcomes of 649patients with hematological malignancies, including 19 patients with sMPMTs (2.9%), and compared the outcomesbetween patients with and without sMPMTs. Results: The overall survival (OS) and disease-free survival (DFS) rates forpatients with sMPMTs were 77% and 70%, respectively, at 2 years; these rates were not statistically different from thosefor patients without sMPMTs (P = .17 and P = .64, respectively). Multivariate analysis showed that the presence ofsMPMTs was not a significant prognostic factor for OS, DFS, or relapse (hazard ratio [HR] 1.48, 95% confidence interval[CI] 0.65-3.38, P = .35; HR 0.97, 95% CI 0.46-2.10, P = .97; and HR 0.79, 95% CI 0.29-2.14, P= .65). In patients withsMPMTs, the order of treatment was not a significant prognostic factor. However, discontinuation of treatment was amarginally favorable factor and might reflect a selection bias. Conclusion: The presence of sMPMTs was not a significantrisk factor for patients with newly diagnosed hematological malignancies. It is important to provide adequatetreatment for both hematological malignancies and solid tumors at the physician’s discretion.